Parry Nutraceuticals

Chennai, India Founded: 1996 • Age: 30 yrs Listed
Nutraceutical production and distribution focusing on micro-algae products and related supplements.
Request Access
Report Incorrect Data
Page last updated

About Parry Nutraceuticals

Parry Nutraceuticals is a publicly listed company based in Chennai (India) founded in 1996. Nutraceutical production and distribution focusing on micro-algae products and related supplements. It operates in the Agriculture and Healthcare sectors. Its Indian entity E.I.D Parry (India) Limited reported revenue of ₹38,883 Cr. Parry Nutraceuticals offers products and services including Organic Spirulina and Organic Chlorella. Its focus areas include Food and Agriculture, Nutraceuticals, Micro-algae Products and Spirulina and Chlorella Manufacturing.

Company details

Parry Nutraceuticals is operated as a division of EID Parry, which is integrated into the Murugappa Group, a conglomerate valued at 5.3 billion USD and established in 1900. It is noted for its 42 years of experience in micro-algae technology, with over 1,500 million doses delivered and adherence to eight international certifications. Products such as Organic Spirulina and Chlorella are distributed in 41 countries, emphasizing traceability, sustainability, purity, and humanity in their processes. The company fosters professionalism with a workforce exceeding 50,000 employees across various businesses.

Operational Areas
Agriculture → Aquaculture Feed and Nutrition
Healthcare → Nutraceutical & Food-as-Medicine Platforms
Key Metrics
  • Market Cap
    ₹11,670 Cr

    EIDPARRY · NSE

  • Share Price
    ₹649.10

    -1.02% today

  • Revenue
    ₹38,534 Cr

    FY 2025-26 · +21.9% YoY

  • EBITDA
    ₹2,971 Cr

    Margin 7.7%

  • Net Profit
    ₹777 Cr

    FY 2025-26 · +163.1% YoY

  • P/E (TTM)
    13.8x

    P/B 1.3x

  • ROE
    19.0%

    ROCE 25.0%

  • Debt / Equity
    0.37

    Interest cover 20.6x

Products & Services of Parry Nutraceuticals

Parry Nutraceuticals offers a comprehensive portfolio of products and services, including Organic Spirulina and Organic Chlorella.

Organic Spirulina
Nutraceutical Products

Organic Spirulina is produced as the only USP verified ingredient, with strict cGMP processes ensured for traceability from raw material to final product stage.

Organic Chlorella
Nutraceutical Products

Organic Chlorella is manufactured to contain the highest levels of Vitamin B12, meeting daily requirements as per recommended guidelines.

Board of directors of E.I.D Parry (India) Limited (Parry Nutraceuticals)

E.I.D Parry (India) Limited is the primary company behind Parry Nutraceuticals. The board of E.I.D Parry (India) Limited currently have 8 directors; the longest-serving is Ramesh K B Menon, appointed in 2017. 28 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ramesh K B Menon
DIN 05275821
Director08 Nov 20178 yrs 11 moE.I.D Parry (India) Limited
Murugappan Muthiah Venkatachalam
DIN 00152619
Director07 Feb 20188 yrs 8 moE.I.D Parry (India) Limited
Ajay Bhaskar Baliga
DIN 00030743
Director09 May 20188 yrs 5 moE.I.D Parry (India) Limited
Krishnakumar Thirumalai
DIN 00079047
Director06 May 20215 yrs 6 moE.I.D Parry (India) Limited
Rangarajan Sridharan
DIN 01814413
Director04 Oct 20215 yrs 1 moE.I.D Parry (India) Limited
Durgashankar Subramaniam
DIN 00044713
Director21 Mar 20224 yrs 7 moE.I.D Parry (India) Limited
Muthiah Murugappan
DIN 07858587
Whole-time director17 May 20224 yrs 5 moE.I.D Parry (India) Limited
Meghna Apparao
DIN 09201659
Director01 Jul 20224 yrs 4 moE.I.D Parry (India) Limited

IPO & Listings of Parry Nutraceuticals

Parry Nutraceuticals is a publicly listed company on the NSE with ticker symbol EIDPARRY in India, operating in the Sugar sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: EIDPARRY
  • Listed entityE.I.D Parry (India) Limited
  • Exchange sectorSugar

Financials of Parry Nutraceuticals

Exchange-reported figures of E.I.D Parry (India) Limited, the listed company behind Parry Nutraceuticals (NSE: EIDPARRY).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹38,534 Cr
+21.9% YoY
EBITDA
₹2,971 Cr
+15.0% YoY
Profit After Tax
₹777 Cr
+163.1% YoY
Net Worth
₹8,766 Cr
+10.5% YoY
Total Assets
₹18,537 Cr
+18.1% YoY
Total Debt
₹3,528 Cr
+30.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue38,53431,60929,41335,24423,52118,55617,129
Revenue growth+21.9%+7.5%-16.5%+49.8%+26.8%+8.3%-
EBITDA2,9712,5832,5883,1562,3611,9771,885
EBITDA margin+7.7%+8.2%+8.8%+9.0%+10.0%+10.7%+11.0%
Profit before tax2,1032,4552,1752,5642,1291,5391,266
Net profit777295870908917516469
Net profit margin+2.0%+0.9%+3.0%+2.6%+3.9%+2.8%+2.7%
EPS (₹)32.0149.4050.6953.3851.1225.2626.43
Balance sheet
Total assets18,53715,69713,03511,2069,3868,0869,613
Net worth8,7667,9367,0586,0855,3264,5833,519
Total debt3,5282,7041,7401,6181,2591,2294,347
Cash & bank1,3093,6913,0311,4661,839793138
Net working capital6,2666,7976,3385,2214,4983,8395,157
Cash flow
Cash from operations1,5421,9361,9743592,2784,7711,986
Cash from investing(173)(2,783)(1,740)487(1,732)(548)(282)
Cash from financing(551)73.84(497)(184)(499)(3,598)(1,769)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9,0187,88210,31211,6248,7206,8118,7209,330
Revenue growth (YoY)+3.4%+15.7%+18.3%+24.6%+29.2%---
Other income29.9348.8459.5315189.7145911769.38
EBITDA7511338351,198805513694959
EBITDA margin+8.3%+1.7%+8.1%+10.3%+9.2%+7.5%+8.0%+10.3%
Depreciation243226204158176142130123
Interest11511910312910496.3698.5993.90
Profit before tax423(162)5881,062615735582811
Tax111125151296151195166219
Net profit312(287)437766464539416592
EPS (₹)7.95(18.74)13.0223.8113.8116.1110.9317.16
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,1203,1682,8092,8952,4962,0241,875
Revenue growth-1.5%+12.8%-3.0%+16.0%+23.3%+8.0%-
EBITDA(1,179)(464)12811320217194.49
EBITDA margin-37.8%-14.7%+4.5%+3.9%+8.1%+8.4%+5.0%
Profit before tax(686)(420)1152453121,058(20.04)
Net profit(7.94)(21.54)87.23280297271(1.80)
Net profit margin-0.3%-0.7%+3.1%+9.7%+11.9%+13.4%-0.1%
EPS (₹)(39.81)(24.09)6.0311.0915.9848.830.10
Balance sheet
Total assets3,2753,8214,0353,4382,9173,2102,819
Net worth1,8732,5402,9192,8822,7602,5941,714
Total debt1,3711,2461,0745471476031,090
Cash & bank6941084.6712.0544.3730.2915.00
Net working capital1,2561,5331,362944347673300
Cash flow
Cash from operations8.72(71.92)(77.70)(367)439(37.08)(15.56)
Cash from investing52162.11(276)76.08269645(31.57)
Cash from financing56.77113346269(690)(605)56.97
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue733846773754760814848755
Revenue growth (YoY)-3.5%+3.9%-8.8%-0.2%+1.1%---
Other income18.8817227.4020544.4713714.94116
Total expenses8001,2518141,1557911,076959796
EBITDA(66.98)(406)(40.70)(402)(30.91)(262)(111)(41.22)
EBITDA margin-9.1%-48.0%-5.3%-53.3%-4.1%-32.2%-13.1%-5.5%
Depreciation39.5145.0146.1145.3944.6544.9945.4343.68
Interest22.2620.3713.9317.2022.2119.2513.8516.23
Profit before tax(110)(299)(73.34)(260)(53.30)(190)(155)14.94
Tax(20.58)41.07(18.99)25.87(25.38)41.97(9.13)(13.31)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 06 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9,0187,88210,31211,6248,7206,8118,7209,330
Revenue growth (YoY)+3.4%+15.7%+18.3%+24.6%+29.2%---
Other income29.9348.8459.5315189.7145911769.38
EBITDA7511338351,198805513694959
EBITDA margin+8.3%+1.7%+8.1%+10.3%+9.2%+7.5%+8.0%+10.3%
Depreciation243226204158176142130123
Interest11511910312910496.3698.5993.90
Profit before tax423(162)5881,062615735582811
Tax111125151296151195166219
Net profit312(287)437766464539416592
EPS (₹)7.95(18.74)13.0223.8113.8116.1110.9317.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue38,53431,60929,41335,24423,52118,55617,129
Revenue growth+21.9%+7.5%-16.5%+49.8%+26.8%+8.3%-
Other income34975730483.42254129130
Total expenses35,56329,02626,82532,08821,16016,57915,243
Employee cost1,3091,035932871771725664
EBITDA2,9712,5832,5883,1562,3611,9771,885
EBITDA margin+7.7%+8.2%+8.8%+9.0%+10.0%+10.7%+11.0%
Depreciation763512421376334332319
Interest454372295298152236430
Profit before tax2,1032,4552,1752,5642,1291,5391,266
Tax723682558737555540377
Net profit777295870908917516469
Net profit margin+2.0%+0.9%+3.0%+2.6%+3.9%+2.8%+2.7%
EPS (₹)32.0149.4050.6953.3851.1225.2626.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital17.7917.7817.7517.7517.7417.7117.70
Reserves & surplus8,7977,9387,0556,0675,3084,5653,502
Shareholders' funds (net worth)8,7667,9367,0586,0855,3264,5833,519
Minority interest6,1534,9964,1543,4542,7742,2461,707
Secured loans2,5401,7361,0511,0567226202,479
Unsecured loans9889686895625376101,868
Total debt3,5282,7041,7401,6181,2591,2294,347
Total liabilities18,53715,69713,03511,2069,3868,0869,613
Assets
Gross block13,25010,0928,3597,0416,5486,0755,978
Net block8,2406,1484,8963,8893,7633,5833,858
Capital work in progress35742252048616020685.35
Investments2,4771,4531,275609563453413
Inventories8,6616,6866,9486,1955,3634,0714,354
Sundry debtors2,3611,7571,8358125738612,116
Cash & bank balances1,3093,6913,0311,4661,839793138
Loans & advances4,3863,1222,7274,1083,0523,1093,822
Total current assets16,71715,25614,54112,58110,8288,83410,430
Total current liabilities10,4518,4598,2037,3606,3304,9955,273
Net working capital6,2666,7976,3385,2214,4983,8395,157
Total assets18,53715,69713,03511,2069,3868,0869,613
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash4041,1761,440778731106171
Net cash from operating activities1,5421,9361,9743592,2784,7711,986
Net cash from investing activities(173)(2,783)(1,740)487(1,732)(548)(282)
Net cash from financing activities(551)73.84(497)(184)(499)(3,598)(1,769)
Net change in cash818(772)(263)66147.18625(64.61)
Closing cash1,3093,6913,0311,4661,839793138
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+21.9%+7.5%-16.5%+49.8%+26.8%+8.3%-
EBITDA growth+15.1%-0.2%-18.0%+33.6%+19.4%+4.9%-
PBT growth-14.3%+12.8%-15.2%+20.4%+38.3%+21.6%+51.3%
Net income growth+163.1%-66.1%-4.1%-1.0%+77.8%+10.1%-
Revenue CAGR (3Y)+3.0%+10.4%+16.6%+27.2%+12.4%+6.5%+6.0%
EBITDA CAGR (3Y)-2.0%+3.0%+9.4%+18.7%+18.2%+17.5%+9.8%
Profitability & leverage
Net income margin+3.6%+5.6%+5.5%+5.2%+6.7%+5.4%+5.2%
Return on capital employed+25.0%+24.2%+29.7%+39.9%+36.6%+25.8%+20.9%
Return on net worth+19.0%+15.9%+24.6%+32.0%+31.8%+24.7%+26.7%
Debt / equity0.370.300.260.250.250.691.42
Long-term debt / equity0.090.090.090.090.100.190.22
Interest cover20.5717.9913.6310.737.4914.3227.48
Efficiency & per share
Fixed asset turnover3.303.433.825.193.733.083.15
Inventory turnover5.024.644.486.104.994.413.39
Debtors turnover18.7117.6022.2350.8832.7812.468.18
EPS (₹)32.0149.4050.6953.3851.1225.2626.43
Dividend per share (₹)0.000.004.009.5011.000.000.00
Book value per share (₹)495.51447.48398.44342.81300.21258.78198.84
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue733846773754760814848755
Revenue growth (YoY)-3.5%+3.9%-8.8%-0.2%+1.1%---
Other income18.8817227.4020544.4713714.94116
Total expenses8001,2518141,1557911,076959796
EBITDA(66.98)(406)(40.70)(402)(30.91)(262)(111)(41.22)
EBITDA margin-9.1%-48.0%-5.3%-53.3%-4.1%-32.2%-13.1%-5.5%
Depreciation39.5145.0146.1145.3944.6544.9945.4343.68
Interest22.2620.3713.9317.2022.2119.2513.8516.23
Profit before tax(110)(299)(73.34)(260)(53.30)(190)(155)14.94
Tax(20.58)41.07(18.99)25.87(25.38)41.97(9.13)(13.31)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,1203,1682,8092,8952,4962,0241,875
Revenue growth-1.5%+12.8%-3.0%+16.0%+23.3%+8.0%-
Other income7482891793022761,101141
Total expenses4,2993,6322,6812,7822,2941,8541,780
Employee cost197201186158135138160
EBITDA(1,179)(464)12811320217194.49
EBITDA margin-37.8%-14.7%+4.5%+3.9%+8.1%+8.4%+5.0%
Depreciation181175147135120120120
Interest73.7168.9144.0536.0346.0992.72136
Profit before tax(686)(420)1152453121,058(20.04)
Tax22.578.718.0947.6928.39194(21.87)
Net profit(7.94)(21.54)87.23280297271(1.80)
Net profit margin-0.3%-0.7%+3.1%+9.7%+11.9%+13.4%-0.1%
EPS (₹)(39.81)(24.09)6.0311.0915.9848.830.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital17.7917.7817.7517.7517.7417.7117.70
Reserves & surplus1,8552,5222,9022,8642,7422,5761,696
Shareholders' funds (net worth)1,8732,5402,9192,8822,7602,5941,714
Secured loans51263882737384.07380840
Unsecured loans85960824817462.67224249
Total debt1,3711,2461,0745471476031,090
Total liabilities3,2753,8214,0353,4382,9173,2102,819
Assets
Gross block2,8762,8122,3982,1461,9911,7521,885
Net block1,3931,6351,3871,2711,2441,1181,329
Capital work in progress6.7125.8328484.1815.0811219.32
Investments6266621,0749921,1191,010999
Inventories1,2781,1581,186979986957957
Sundry debtors184289241207146201162
Cash & bank balances6941084.6712.0544.3730.2915.00
Loans & advances140422391138166425417
Total current assets2,2961,9771,8221,3351,3421,6131,551
Total current liabilities1,0414444613919959401,250
Net working capital1,2561,5331,362944347673300
Total assets3,2753,8214,0353,4382,9173,2102,819
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1051.329.4230.9113.3810.540.70
Net cash from operating activities8.72(71.92)(77.70)(367)439(37.08)(15.56)
Net cash from investing activities52162.11(276)76.08269645(31.57)
Net cash from financing activities56.77113346269(690)(605)56.97
Net change in cash587103(8.10)(21.49)17.532.849.84
Closing cash6941084.6712.0544.3730.2915.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-1.5%+12.8%-3.0%+16.0%+23.3%+8.0%-
EBITDA growth-154.0%-463.9%+12.5%-43.9%+18.6%+80.5%-
PBT growth-63.4%--52.9%-21.6%-70.5%+9998.0%-
Net income growth+63.1%-124.7%-68.9%-5.6%+9.5%--
Revenue CAGR (3Y)+2.5%+8.3%+11.5%+15.6%+10.6%+1.8%-5.9%
EBITDA CAGR (3Y)---9.2%+6.3%-+28.7%-35.1%
Profitability & leverage
Net income margin-22.7%-13.5%+3.8%+6.8%+11.4%+42.7%+0.1%
Return on capital employed+4.4%+1.7%+3.7%+12.3%+11.7%+14.1%+4.2%
Return on net worth-0.4%-0.8%+3.0%+9.9%+10.6%+12.6%-0.1%
Debt / equity0.590.420.280.120.140.390.56
Long-term debt / equity0.060.070.060.050.040.130.24
Interest cover-5.42-10.77-221.25-166.1156.17183.46-541.12
Efficiency & per share
Fixed asset turnover1.101.221.241.401.331.111.04
Inventory turnover2.562.702.592.952.572.121.94
Debtors turnover13.1911.9612.5516.4314.4211.1711.59
EPS (₹)(39.81)(24.09)6.0311.0915.9848.830.10
Dividend per share (₹)0.000.004.009.5011.000.000.00
Book value per share (₹)105.27142.84164.47162.38155.59146.4896.82

Web traffic of Parry Nutraceuticals

The website of Parry Nutraceuticals (parrynutraceuticals.com) receives about 1.8K visits a month.

  • Monthly visits
    1.8K

    ▼ 75.1% vs previous month

Top companies in Aquaculture Feed and Nutrition

3 companies that operate in the same segment as Parry Nutraceuticals (Aquaculture Feed and Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Avanti Feeds
Feeds for fish and shrimp are manufactured and specialized in.
1993Hyderabad, Telangana, IndiaUSD 638.11 M773
Waterbase
Fully integrated company in aqua feed production, and farming, processing, and supply of shrimp products
1987Chennai, Tamil Nadu, IndiaUSD 35.49 M
Karyotica
Develops innovative probiotics, enzymes, and prebiotics for animal health and sustainable aquaculture.
2002Hyderabad, Telangana, IndiaUSD 1.55 M35
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Parry Nutraceuticals

Parry Nutraceuticals ventures out with Synthite
FFOODS Spectrum • 8 years ago
Parry Nutraceuticals JV to make high-value algae products, eyes Europe, US
Business Standard • 8 years ago
Parry Nutraceuticals and Synthite Industries Forge Partnership for Extraction of Phycocyanin
NewsVoir • 9 years ago
Parry Nutraceuticals’ Indian Microalgae Facility Receives U.S. FDA Approval; Ramps up New Product Development
NewsVoir • 9 years ago
Parry Nutraceuticals gets USFDA nod for micro-algae facility
Business Line • 9 years ago
Premium access

Complete news archive for Parry Nutraceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Parry Nutraceuticals

Parry Nutraceuticals was founded in 1996.

Parry Nutraceuticals is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.

The primary company behind Parry Nutraceuticals, E.I.D Parry (India) Limited, reported revenue of ₹38,883 Cr for FY 2026, up 22% year on year.

Parry Nutraceuticals is operated as a division of EID Parry, which is integrated into the Murugappa Group, a conglomerate valued at 5.3 billion USD and established in 1900. It is noted for its 42 years of experience in micro-algae technology, with over 1,500 million doses delivered and adherence to eight international certifications. Products such as Organic Spirulina and Chlorella are distributed in 41 countries, emphasizing traceability, sustainability, purity, and humanity in their processes. The company fosters professionalism with a workforce exceeding 50,000 employees across various businesses.

Parry Nutraceuticals offers Organic Spirulina and Organic Chlorella.

Yes, Parry Nutraceuticals is publicly traded on NSE under the ticker symbol EIDPARRY.

Parry Nutraceuticals operates through E.I.D Parry (India) Limited.

The legal entities of Parry Nutraceuticals currently have 10 directors, including Meghna Apparao, Ajay Bhaskar Baliga, Murugappan Muthiah Venkatachalam and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available